Johnson & Johnson group Janssen Biotech has inked deal with Novo Nordisk acquiring an undisclosed development program focused on autoimmune diseases.
Details on the deal are thin, but it was announced that the exclusive licence relates to a programme targeting modulation of certain immune cells via a cell surface receptor (NKG2D receptor).
Further terms were not disclosed, and the agreement remains subject to final clearance under the Hart-Scott-Rodino Antitrust Improvements Act, Novo said.
